Increased detection of clinically significant prostate cancer by additional sampling from the anterior lateral horns of the peripheral zone in combination with the standard sextant biopsy

International Journal of Urology

Volumn 11, Issue 6, 2004, Pages 402-406

  Miyake, Hideaki ^a   Sakai, Iori ^a   Harada, Ken Ichi ^a   Hara, Isao ^b   Eto, Hiroshi ^a  

^a HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^b KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Insignificant cancer; Needle biopsy; Prostate cancer

Indexed keywords

ADULT; AGED; ARTICLE; CANCER CYTODIAGNOSIS; CANCER INVASION; CONTROLLED STUDY; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEEDLE BIOPSY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SAMPLING; SEXTANT BIOPSY;

AGED; BIOPSY, NEEDLE; HUMANS; MALE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 3042698506     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00821.x     Document Type: Article

References (25)

1. Selzman AA, Resnick MI. Transrectal ultrasound and prostate biopsy. Semin. Urol. 1994; 12: 265-73.
2. Hodge KK, McNeal JE, Terris MK et al. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol. 1989; 142: 71-4.
3. Rabbani F, Stroumbakis N, Kava BR et al. Incidence and clinical significance of false-negative sextant prostate biopsies. J. Urol. 1998; 159: 1247-50.
4. Epstein JI, Walsh PC, Sauvageot J et al. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J. Urol. 1997; 158: 1886-90.
5. Norberg M, Egevad L, Holmberg L et al. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 1997; 50: 562-6.
6. Babaian RJ, Toi A, Kamoi K et al. A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J. Urol. 2000; 163: 152-7.
7. Presti JC, Chang JJ, Bhargava V et al. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J. Urol. 2000; 163: 163-7.
8. Taylor JA, Gancarczyk KJ, Fant GV et al. Increasing the number of core samples taken at prostate needle biopsy enhances the detection of clinically significant prostate cancer. Urology 2002; 60: 841-5.
9. Goto Y, Ohori M, Arakawa A et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J. Urol. 1996; 156: 1059-63.
10. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J. Urol. 1998; 160: 2407-11.
11. Stamey TA, McNeal JE, Freiha FS et al. Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol. 1988; 139: 1235-41.
12. Chan TY, Chan DY, Stutzman KL et al. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J. Urol. 2001; 166: 2181-4.
13. Park SJ, Miyake H, Hara I et al. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int. J. Urol. 2003; 10: 68-71.
14. Hara I, Miyake H, Hara S et al. Value of serum prostate specific antigen-alpha1-antichymotrypsin complex and its density as a predictor for the extent of prostate cancer. BJU Int. 2001; 88: 53-7.
15. International Union Against Cancer. TNM Classification of Malignant Tumors, 5th edn. John Wiley & Sons, New York, USA, 1997.
16. Grossklasus DJ, Coffey CS, Shappell SB et al. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy. J. Urol. 2002; 167: 2031-6.
17. Naughton CK, Miller DC, Mager DE et al. A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J. Urol. 2000; 164: 388-92.
18. Terris MK, Pham TQ, Issa MM et al. Routine transition zone and seminal vesicle biopsies in all patients undergoing transrectal ultrasound guided prostate biopsies are not indicated. J. Urol. 1997; 157: 204-6.
19. Partin AW, Epstein JI, Cho KR et al. Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathologic stage in stage B prostate cancer. J. Urol. 1989; 141: 341-5.
20. Epstein JI, Walsh PC, Carmichael M et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74.
21. Goldstein NS, Begin LR, Grody WW et al. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the 'vanishing cancer phenomenon.' Am. J. Surg. Pathol. 1995; 19: 1002-9.
22. DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am. J. Surg. Pathol. 1997; 21: 174-8.
23. Eskew LA, Woodruff RD, Bare RL et al. Prostate cancer diagnosed by the 5 region biopsy method is significant disease. J. Urol. 1998; 160: 794-6.
24. Brossner C, Bayer G, Madersbacher S et al. Twelve prostate biopsies detect significant cancer volumes (>0.5 ml). BJUInt. 2000; 85: 705-7.
25. Manseck A, Froehner M, Oeslschlager S et al. Is systematic biopsy suitable for the detection of clinically significant prostate cancer? Urol. Int. 2000; 65: 80-83.